Who is sponsoring NCT01529320?

NCT01529320 is sponsored by Fundacion IMIM.

What drugs are being tested in NCT01529320?

Interventions in NCT01529320: Adventan® (methylprednisolone aceponate 0,1%).

What condition does NCT01529320 study?

NCT01529320 studies Allergic Contact Eczema.

Is NCT01529320 still recruiting?

NCT01529320 is currently completed. Last updated 11 May 2016.

Last reviewed 2016-05-11 · How we verify

NCT01529320

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study).

Completed Phase 1 Last updated 11 May 2016

What this trial tests

Phase 1 trial testing Adventan® (methylprednisolone aceponate 0,1%) in Allergic Contact Eczema in 18 participants. Completed in 1 May 2012.

Timeline

1 February 2012

Primary endpoint
1 May 2012

1 May 2012

Quick facts

Lead sponsor	Fundacion IMIM
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	supportive care
Enrollment	18
Start date	1 February 2012
Primary completion	1 May 2012
Estimated completion	1 May 2012
Sites	1 location across Spain

Drugs / interventions tested

Adventan® (methylprednisolone aceponate 0,1%) — full drug profile →

Conditions studied

Allergic Contact Eczema — all drugs for Allergic Contact Eczema →

Sponsor

Fundacion IMIM — full company profile →

Who can join

18 and older, any sex, with Allergic Contact Eczema. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean time to Itch Relief (TR) from the start of treatment, with methylprednisolone aceponate.
Time frame: 5 days
Time to Itch Relief is defined as the time needed to reach a 30% decrease of the maximum VAS (Visual Analogue Scale used for self-assessment of itch by the volunteers) recorded after the start of treatment.

Sponsor's own description

Determine the mean time to itch relief from the start of treatment with topic methylprednisolone aceponate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01529320 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion IMIM
Last refreshed: 11 May 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01529320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing